ReviewFrontiers in immunology2026
Cancer immunoediting in the melanoma tumor microenvironment: from immune elimination to therapeutic resistance.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor immunoediting is a dynamic process of interaction between the host immune system and tumor cells and encompasses three sequential phases: elimination, equilibrium, and escape. It plays a central regulatory role in melanoma initiation, progression, and therapeutic response. Currently, increasing attention has been directed toward the complexity of the melanoma tumor microenvironment, in which functional dysregulation of immune cell subsets, imbalance of cytokine networks, and alterations in the metabolic milieu collectively drive the process of immunoediting. However, most existing studies have focused on individual phases or isolated factors, and a comprehensive understanding of the entire immunoediting process and its systematic associations with tumor heterogeneity and resistance to immunotherapy remains insufficient. This review summarizes recent advances in tumor immunoediting within the melanoma tumor microenvironment, with particular emphasis on the regulatory mechanisms through which individual components of the immune microenvironment influence different phases of immunoediting, providing a theoretical basis for optimizing melanoma immunotherapy and identifying novel therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.